



## Sanofi Ranks Third on the *Access to Medicine Foundation's 2012 ATM Index*

**Paris, France - November 28, 2012** - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it ranked third among twenty pharmaceutical companies on the **2012 Access to Medicine Index** (ATM Index) created by the **Access to Medicine Foundation**, an international non-profit organization dedicated to improving access to medicine to societies in need.

*"This third ranking on the 2012 Access to Medicine Index is a recognition of Sanofi's efforts to act with all our partners to protect health and raise the hopes of patients,"* said Gilles Lhernould, Senior Vice President, Corporate Social Responsibility, Sanofi. *"The key challenge in the future will be to eliminate the north-south divide in access to health care. As a global health care leader, we are the right partner to achieve this goal."*

The *Access to Medicine Foundation* particularly welcomes the initiatives of Sanofi in the fields of multi-resistant bacterial infections, malaria, tuberculosis and Neglected Tropical Diseases, as well as the renewal of its partnership with the World Health Organization to fight those diseases, including Buruli ulcer, Human African trypanosomiasis (sleeping sickness), Chagas disease and leishmaniasis.

In its report, the *Access to Medicine Foundation*, creator of the ATM 2012 Index, highlights that Sanofi has significantly improved its approach to access to medicine in several areas and it leads the field in the area of public policy. It has continued to invest in research and development, targeting relevant diseases, and has a broad range of molecules in its pipeline. The company has robust access management systems, inter- and intra-country tiered pricing, works with local governments to improve capability advancement and has initiatives in both donations and sustainable philanthropy, with two single-drug donation programs.

The goal of the *Access to Medicine Index* is to supply pharmaceutical companies, investors, governments, academics, nongovernmental organizations and the general public with independent, impartial and reliable information on individual pharmaceutical companies' efforts to improve global access to medicine. The *Access to Medicine Foundation* strives to provide companies with a transparent means by which pharmaceutical companies assess, monitor and improve their own performance and their public and investment profiles while building a platform on which all stakeholders can share best practices in the area of global access to medicine

\*\*\*

### **About Sanofi Access to Medicines**

[http://csrreporting.sanofi.com/web/patient/access\\_healthcare/commitment/policy\\_access\\_medicines](http://csrreporting.sanofi.com/web/patient/access_healthcare/commitment/policy_access_medicines)

### **About Sanofi**

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

---

### **Contacts**

#### **Sanofi Media Relations**

Frédéric Lemonde-San

Tel: +33 (0) 1 53 77 91 55

E-mail: [frederic.lemonde@sanofi.com](mailto:frederic.lemonde@sanofi.com)